News Articles
Sector/Industry
Please Select
Company
16 September, 2024
Memphasys achieves positive initial study results from Felix equine application
Australian bioseperation biotechnology company Memphasys (ASX: MEM) has obtained positive results from an initial study validating the commercial potential of its Felix System in improving the...
12 September, 2024
Memphasys to Raise $2 Million for Felix Commercialisation Push
In the world of biotech, timing is everything, and for Memphasys Limited (ASX: MEM), the clock is ticking as it gears up to unlock the commercial potential of its flagship Felix™ System. The...
22 August, 2024
ABx receives R&D Tax Rebate for ALCORE
ABx Group's (ASX: ABX) 83%-owned subsidiary ALCORE Limited has received a research & development (R&D) tax offset of $474,126.21 from the Australian Taxation Office (ATO) for activities undertaken...
29 July, 2024
Memphasys secures $1M from major shareholder and R&D Tax Rebate loan
Australian reproductive biotechnology company Memphasys Limited’s (ASX: MEM) major shareholder Andrew Goodall has entered into a Subscription Agreement with the company to raise $500,000.
22 July, 2024
Little Green Pharma delivers robust quarter
Little Green Pharma Ltd (ASX: LGP) has reported a robust performance in its quarterly activities report and Appendix 4C for the quarter ending 30 June 2024. The company achieved revenues of $7.3...